pharma · Hypertriglyceridemia · Type 2 Diabetes Mellitus · IONS
IONIS PHARMACEUTICALS
IONIS PHARMACEUTICALS INC
IONIS PHARMACEUTICALS patent portfolio — 222 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 2855 Gazelle Ct, Carlsbad, CA 92010, US
- Founded
- 1989
- Employees
- 1,493
- Programs
- 128
- Drugs
- 48
- Patents
- 222
IONIS PHARMACEUTICALS patents
222 pharmaceutical patents indexed for IONIS PHARMACEUTICALS. 0 expire within 24 months.
IONIS PHARMACEUTICALS has 222 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 9644207
Compositions and methods for modulating Tau expression
granted -
US 9624496
Modulation of apolipoprotein C-III expression
granted -
US 9617539
Modulation of UBE3A-ATS expression
granted -
US 9617540
Compounds and methods for modulating gene expression
granted -
US 9605259
Compounds and methods for modulating protein expression
granted -
US 9605263
Compositions for modulating C9ORF72 expression
granted -
US 9598693
Oligomeric compounds and compositions for the use in modulation of micrornas
granted -
US 9593333
Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
granted -
US 9574193
Methods and compositions for modulating apolipoprotein (a) expression
granted -
US 9567588
Modulation of androgen receptor expression
granted -
US 9567587
Antisense modulation of GCCR expression
granted -
US 9550988
Antisense compounds
granted -
US 9546368
Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression
granted -
US 9540641
Cancer treatment
granted -
US 9523094
Methods of treating kennedy's disease
granted -
US 9518259
Compounds and methods for modulating interaction between proteins and target nucleic acids
granted -
US 9487780
Antisense compounds targeting genes associated with fibronectin
granted -
US 9476051
Antisense modulation of superoxide dismutase 1, soluble expression
granted -
US 9428750
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
granted -
US 9409934
Cyclohexenyl nucleic acids analogs
granted -
US 9404113
Antisense modulation of PTP1B expression
granted -
US 9404114
Antisense modulation of GCGR expression
granted -
US 9399774
Modulation of transthyretin expression
granted -
US 9365848
Modulation of apolipoprotein C-III expression
granted -
US 9353372
Compositions and their uses directed to huntingtin
granted -
US 9340784
Methods and compositions for modulating alpha-1-antitrypsin expression
granted -
US 9322021
Methods for modulating kallikrein (KLKB1) expression
granted -
US 9321799
Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
granted -
US 9315811
Methods for modulating kallikrein (KLKB1) expression
granted -
US 9273315
Modulation of huntingtin expression
granted
Frequently asked questions
How many patents does IONIS PHARMACEUTICALS have?
222 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do IONIS PHARMACEUTICALS patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.